Page last updated: 2024-12-11

1-(3-amino-7-methoxy-1-pyrazolo[3,4-b]quinolinyl)-2-(4-chlorophenyl)ethanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you described, **1-(3-amino-7-methoxy-1-pyrazolo[3,4-b]quinolinyl)-2-(4-chlorophenyl)ethanone**, is a complex organic molecule with potential biological activity. Here's a breakdown:

**Structure and Properties:**

* **Pyrazolo[3,4-b]quinoline:** This core structure is a fused ring system containing both a pyrazole and a quinoline ring.
* **Substituents:** The molecule has various substituents attached to this core structure:
* **3-amino:** An amino group (-NH2) at the 3rd position of the pyrazole ring.
* **7-methoxy:** A methoxy group (-OCH3) at the 7th position of the quinoline ring.
* **1-(4-chlorophenyl)ethanone:** A 4-chlorophenyl ketone group attached to the 1st position of the pyrazole ring.

**Potential Importance for Research:**

This compound is likely of interest for research due to its structural similarity to known bioactive molecules. Here's why:

* **Pyrazoloquinoline Analogues:** Pyrazolo[3,4-b]quinolines are a class of compounds with diverse pharmacological activities. Some examples include:
* **Anti-cancer agents:** Several pyrazoloquinolines have shown promising activity against various cancer cell lines.
* **Anti-inflammatory agents:** Some compounds in this class have been investigated for their anti-inflammatory potential.
* **Anti-microbial agents:** Pyrazoloquinolines have also been studied for their antimicrobial properties.
* **Chlorophenyl Ketone Group:** This group is commonly found in pharmaceuticals and can influence the molecule's ability to interact with biological targets.

**Further Research:**

Without more information, it's impossible to say exactly why this specific compound is being studied. However, its structure suggests potential for research in areas such as:

* **Drug discovery:** Investigating this compound's biological activity could lead to the development of new therapeutic agents.
* **Medicinal chemistry:** Studying the molecule's interactions with biological targets can help researchers understand the structure-activity relationships of this class of compounds.
* **Synthesis and characterization:** Developing efficient methods to synthesize and purify this compound is crucial for further research.

**Key Points:**

* This compound is likely being studied for its potential biological activity, particularly in areas related to medicine and drug discovery.
* Its structural similarity to known bioactive molecules makes it a promising candidate for further investigation.
* Additional research is needed to fully understand its properties and potential applications.

Cross-References

ID SourceID
PubMed CID6619057
CHEMBL ID1303886
CHEBI ID115715

Synonyms (20)

Synonym
MLS000522343 ,
smr000127611
IDI1_004256
CHEMDIV2_005541
CHEBI:115715
HMS1384L19
AKOS001763975
1-(3-amino-7-methoxy-1h-pyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)-1-ethanone
1-(3-amino-7-methoxypyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)ethanone
CHEMBL1303886
HMS2257I03
1-(3-amino-7-methoxy-1-pyrazolo[3,4-b]quinolinyl)-2-(4-chlorophenyl)ethanone
1-(3-amino-7-methoxy-pyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)ethanone
1-(3-azanyl-7-methoxy-pyrazolo[3,4-b]quinolin-1-yl)-2-(4-chlorophenyl)ethanone
cid_6619057
bdbm40184
HMS3433K10
Q27198066
SR-01000119236-1
sr-01000119236
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.10000.100020.879379.4328AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency3.66260.004110.890331.5287AID504467
67.9K proteinVaccinia virusPotency2.51190.00018.4406100.0000AID720579
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
huntingtin isoform 2Homo sapiens (human)Potency7.94330.000618.41981,122.0200AID1688
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency89.12510.425612.059128.1838AID504891
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency17.78280.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency20.59620.004611.374133.4983AID624296
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency14.12540.00419.962528.1838AID2675
Guanine nucleotide-binding protein GHomo sapiens (human)Potency11.22021.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptor 1Homo sapiens (human)IC50 (µMol)24.78332.161613.689226.3472AID713
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]